“Ophthalmic Drug Delivery” magazine features Nemera’s article about the development of an efficient ophthalmic device combination product.
The recently published “Ophthalmic Drug Delivery” magazine includes an article from Nemera: “DEVELOPING AN EFFICIENT OPHTHALMIC DEVICE COMBINATION PRODUCT”.
In this article, Zoë Davidson, Global Category Manager, Ophthalmic Products, Nemera, looks at how understanding the patient journey can help develop an efficient ophthalmic device combination product.
A significant patient population suffers from conditions requiring long-term daily use of eye drops. Dry eye syndrome is associated with aging, contact lens use and environmental factors.
The majority of eye drops today contain preservatives to maintain the formulation’s sterility.
We developed Novelia, which is a multi-dose closing tip system that avoids the need for preservatives in the drug and prevents bacterial contamination over the duration of treatment.
Nemera’s alternative to the use of sterile filters for multi-dose preservative-free eye droppers is a non-return valve system used in conjunction with a silicone membrane to filter the returning air allows by PureFlow technology.
Novelia is not only a product but a platform, designed and developed with patients in mind. The demands of the ophthalmic market are increasingly varied in terms of new formulations and compositions. That’s why adaptability is a key criterion for Nemera.
With Novelia, you can choose from a range of valves, PureFlow and bottle sizes, depending on your specific formulation.
We are developing a connected device for Novelia which has a role in helping patients with adherence.
Nemera’s answer to challenge the issue of poor adherence and improve the patient’s experience is the development of e-Novelia – an add-on device to Nemera’s existing preservative-free multi-dose eye dropper.
Using smart add-on technology, the patient benefits from digitalized and interactive instructions via their smartphone. Key features include providing patients with reminders on when to take their next dose and when to replace their medication, for example.
To learn more about Novelia and e-Novelia, come to meet us on our booth C56
at Pharmapack 2020 in Paris.
The full article:
The full issue of the magazine:
Nemera is a world leader in the design, development, and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generics industries. Nemera offers a comprehensive portfolio of products and services across ophthalmology, nasal, inhalation, dermal, transdermal and parenteral delivery. Nemera’s vision is to be the most patient-centric drug delivery device company. Nemera always puts patients first, providing high-quality solutions that have a demonstrable impact on patients’ health
Nemera’s newly branded Insight Innovation Center, with offices in North America and Europe, provides consultative services to support your overall device strategy. Providing user research, Human Factors, User Experience design, and Design for manufacturing, the Insight Innovation Center can help customers navigate their device strategy for both novel and platform solutions. Users are at the center of everything that we do in our effort to always put patients first.